Following this transaction, Patel now instantly owns 5,547,102 shares of the corporate. This acquisition displays Patel’s continued funding in Greenwich LifeSciences, a pharmaceutical firm based mostly in Stafford, Texas, which presently maintains a market capitalization of $172.33 million. InvestingPro evaluation reveals the inventory’s excessive volatility with a beta of three.3, whereas analysts have set a goal worth of $38 per share. Uncover extra precious insights and seven extra ProTips with an InvestingPro subscription. Following this transaction, Patel now instantly owns 5,547,102 shares of the corporate. This acquisition displays Patel’s continued funding in Greenwich LifeSciences, a pharmaceutical firm based mostly in Stafford, Texas, which presently maintains a market capitalization of $172.33 million. InvestingPro evaluation reveals the inventory’s excessive volatility with a beta of three.3, whereas analysts have set a goal worth of $38 per share. Uncover extra precious insights and seven extra ProTips with an InvestingPro subscription.
In different latest information, Greenwich LifeSciences reported outcomes from its Annual Assembly of Stockholders. The assembly resulted within the re-election of all 5 director nominees, indicating sturdy assist for the corporate’s management, with over 7.8 million votes for every director. The corporate’s impartial registered public accounting agency, RBSM, LLP, was additionally ratified for the fiscal 12 months ending December 31, 2024, receiving over 9 million votes in favor.
A major modification to the corporate’s 2019 Fairness Incentive Plan was accredited, growing the variety of shares reserved for issuance below the plan to 4 million from the earlier 1.5 million shares. This proposal obtained over 8 million votes in favor.
These latest developments replicate the shareholders’ assist for Greenwich LifeSciences’ strategic initiatives. InvestingPro evaluation signifies that whereas the corporate isn’t presently worthwhile, analysts have set an formidable worth goal of $38. The corporate maintains sturdy liquidity with a present ratio of 6.91, indicating stable short-term monetary stability.
This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.
